Is Low-Molecular-Weight Heparin the Answer for the Therapy of Acute Deep Vein Thrombosis?

Endovascular caval interruption in pregnant patients with deep vein thrombosis of the lower extremity

“…[24][25][26] Recently, several studies have reported on the safety of the use of low-molecular weight heparin in pregnancy. [27][28][29][30][31] Low-molecular weight heparin is an attractive alternative to unfractionated heparin, because of its association with a lower incidence of osteoporosis and heparin-induced thrombocytopenia and possibly less bleeding. Low-molecular weight heparin has been recommended for both DVT prophylaxis and treatment for venous thromboembolism during pregnancy.…”

“…It is attractive for the long-term management of DVT in pregnant patients, because it lacks teratogenic properties, does not penetrate the placenta, and is detected at negligible levels in the maternal milk, with minimal side effects to the mother or fetus. [27][28][29][30][31] Enson and Stevenson 31 conducted a systematic review with Medline and Cochrane Library data base searches and a bibliography review of English-language reports describing therapy with low-molecular weight heparin in pregnancy. They concluded that the published experience suggested that low-molecular weight heparin is generally safe and effective when administered for thromboprophylaxis during pregnancy.…”